Respiratory News and Research

RSS

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Bronchiectasis independently associated with increased mortality risk in COPD patients

Bronchiectasis is independently associated with an increased mortality risk in patients with moderate-to-severe COPD, according to a new study from researchers in Spain.

10 Feb 2013

Older adults with COPD more frequently use benzodiazepines

A popular class of drugs commonly used to treat sleep and mood symptoms continues to be frequently prescribed despite being known to have potentially life-threatening side effects.

9 Feb 2013

High prevalence of total knee replacement revealed

Research highlights the growing use of total knee replacement in the USA among patients with osteoarthritis and the associated healthcare burden.

8 Feb 2013

Microbial composition of induced sputum altered in mild asthma

The microbial composition of sputum in patients with mild asthma differs from that in individuals without the condition, results from a US study show.

8 Feb 2013

eGFR ‘powerful’ operative risk gauge

Patients’ estimated glomerular filtration rate is highly predictive of their risk for dying after surgery, shows a systematic review and meta-analysis.

8 Feb 2013

Conference attendees express concern over growing burden of NCDs

Inter Press Service reports on "a conference organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on World Cancer Day [February 4] in Geneva," during which experts warned about the growing burden of non-communicable diseases (NCDs) -- "cancer, heart disease, diabetes and chronic respiratory diseases, among others" -- especially in low- and middle-income countries.

7 Feb 2013

Combination RT offers hope to late-stage esophageal cancer patients

Just over half of patients with advanced-stage esophageal cancer who are unsuitable for standard curative treatment survive for a year after receiving a combination of external beam radiotherapy and high-dose rate brachytherapy, report researchers.

7 Feb 2013

Chlorhexidine bathing protects vulnerable hospital patients

Bathing hospital patients with chlorhexidine-impregnated washcloths reduces the risk for them acquiring multidrug-resistant organisms and developing bloodsteam infections, show study findings.

7 Feb 2013

Glimmer of hope for imatinib-resistant GIST

The monoclonal antibody SR1 can significantly inhibit gastrointestinal stromal tumor cell growth, report researchers in the Proceedings of the National Academy of Sciences.

7 Feb 2013

Start palliative care early for optimum results

Palliative care provided early in the ambulatory care setting varies with the trajectory of patients’ disease and is complementary to medical management, show study results.

6 Feb 2013

‘Elephant in the room’ adds to rectal surgery costs

Anastomotic leakage occurs after one in 10 anterior resection procedures and costs English hospitals up to £ 3.5 milion per year, research shows.

6 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013